tricare and glp 1 Impact of Tricare's GLP-1 Coverage Cuts on Military Families NEW: Tricare For Life &

According to the EMAs findings, people who take Ozempic are two times more likely to experience a condition that causes sudden, potentially irreversible vision loss

Forbes contributor Bruce Japsen reported in June 2026 that a growing share of health plans and employers are refusing to cover the drugs for weight loss, restricting coverage to diabetes indications or requiring prior authorisation hurdles that most patients cannot clear

Consistent with this concept, up to 30% of individuals with PsO eventually develop PsA, a chronic inflammatory arthropathy affecting peripheral joints, entheses, and the axial skeleton ( Early PsA may display nonspecific musculoskeletal symptoms, such as inflammatory arthralgia or morning stiffness, even in the absence of overt synovitis or radiographic erosions ( At the pathogenic level, PsO and PsA share core inflammatory mechanisms driven by dysregulation of the IL17/IL23 and Tumour Necrosis Factor (TNF)- cytokine axes ( These immune pathways are closely intertwined with metabolic abnormalities, particularly obesity and adipose tissue dysfunction

GLP-1 medications also carry an FDA black box warning for risk of thyroid C-cell tumors, and should not be used by patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2)

Compounding offers speed, customization, and price advantagesbut with regulatory gray zones

When the shortages subside, compounding pharmacies may no longer offer these medications, leaving those who rely on them scrambling for alternatives